Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced a board meeting scheduled for August 18, 2025, to approve and release the interim results for the first half of the year. This announcement indicates the company’s ongoing commitment to transparency and stakeholder engagement, with a live webcast planned to discuss the results, reflecting its proactive communication strategy.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and production of biopharmaceutical products. It operates in the healthcare industry, providing innovative medical solutions and contributing to advancements in biotechnology.
Average Trading Volume: 824,900
Technical Sentiment Signal: Buy
Current Market Cap: HK$94.49B
See more data about 6990 stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money